Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 9/2016

01-09-2016 | Pictorial Essay

Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging

Authors: Stephanie Channual, Anokh Pahwa, David S. Lu, Steven S. Raman

Published in: Abdominal Radiology | Issue 9/2016

Login to get access

Abstract

Gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a unique hepatocyte-specific contrast agent approved for clinical use in the United States in 2008. Gd-EOB-DTPA-enhanced MR has shown to improve detection and characterization of hepatic lesions. Gd-EOB-DTPA is now being routinely used in daily clinical practice worldwide. Therefore, it is important for radiologists to be familiar with the potential uses and pitfalls of Gd-EOB-DTPA, which extends beyond the assessment of focal hepatic lesions. The purpose of this article is to review the various usages of Gd-EOB-DTPA in hepatobiliary MR imaging.
Literature
1.
Gomaa AI, Khan S, Toledano MB, Waked I, Taylor-Robinson SD (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14:4300–4308CrossRefPubMedPubMedCentral
2.
Liu CL, Fan S, Lo CM, et al. (2004) Hepatic resection for incidentaloma. J Gastrointest Surg 8:785–793CrossRefPubMed
3.
Hammerstingl R, Huppertz A, Breuer J, et al. (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457–467CrossRefPubMed
4.
Huppertz A, Haraida S, Kraus A, et al. (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observations. Radiology 234:468–478CrossRefPubMed
5.
Cruite I, Schroeder M, Merkle EM, Sirlin CB (2010) Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 195:29–41CrossRefPubMed
6.
Gall TM, Oniscu G, Madhavan K, Parks RW, Garden OJ (2009) Surgical management and longterm follow-up of non-parasitic hepatic cysts. HPB (Oxford) 11:235–241CrossRef
7.
Huppertz A, Haraida S, Kraus A, et al. (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observations. Radiology 234(2):468–478CrossRefPubMed
8.
Lee NK, Kim S, Lee JW, et al. (2009) Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 29(6):1707–1724CrossRefPubMed
9.
Rungsinaporn KP, Phaisakamas T (2008) Frequency of abnormalities detected by upper abdominal ultrasound. J Med Assoc Thai 91(7):1072–1075PubMed
10.
Tamada T, Ito K, Yamamoto A, et al. (2011) Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 196(4):824–830CrossRefPubMed
11.
Tateyama A, Fukukura Y, Takumi K, et al. (2012) Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography. World J Gastroenterol 18(43):6269–6276CrossRefPubMedPubMedCentral
12.
Agarwal S, Grajo J, Fuentes-Orrego JM, et al. (2016) Distinguishing hemangiomas from metastases on liver MRI performed with gadoxetate disodium: value of the extended washout sign. Eur J Radiol 85:635–640CrossRefPubMed
13.
Herman P, Pugliese V, Machado MA, et al. (2000) Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 22(6):1674–1681
14.
Sutherland T, Seale M, Yap K (2014) Part 1: MRI features of focal nodular hyperplasia with an emphasis on hepatobiliary contrast agents. J Med Imaging Radiat Oncol 58(1):50–55CrossRefPubMed
15.
Seale MK, Catalano O, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748CrossRefPubMed
16.
Barthelmes L, Tait I (2005) Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 7:186–196CrossRef
17.
Khanna M, Ramanathan S, Fasih N, et al. (2015) Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma. Insights Imaging 6(3):347–362CrossRefPubMedPubMedCentral
18.
Grazioli L, Olivetti L, Mazza G, Bondioni MP (2013) MR imaging of hepatocellular adenomas and differential diagnosis dilemma. Int J Hepatol.
19.
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515–524CrossRefPubMed
20.
Micchelli ST, Vivekanandan P, Boitnott JK, et al. (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21:491–497CrossRefPubMed
21.
Tse JR, Naini B, Lu DS, Raman SS (2015) Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology 27:142449
22.
Wanless IR (1990) Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11:787–797CrossRefPubMed
23.
Tanaka M, Wanless I (1998) Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 27:488–496CrossRefPubMed
24.
Maetani Y, Itoh K, Egawa H, et al. (2002) Benign hepatic nodules in Budd-Chiari syndrome: radiologic-pathologic correlation with emphasis on the central scar. AJR Am J Roentgenol 178:869–875CrossRefPubMed
25.
Brancatelli G, Federle M, Grazioli L, Golfieri R, Lencioni R (2002) Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR Am J Roentgenol 178:877–883CrossRefPubMed
26.
Bureau CPJ, Péron J, Sirach E, et al. (2004) Liver nodules resembling focal nodular hyperplasia after portal vein thrombosis. Journal of hepatology 41:499–500CrossRefPubMed
27.
Duvoux C, Kracht M, Lang P, et al. (1991) Nodular regenerative hyperplasia of the liver associated with azathioprine therapy. Gastroenterol Clin Biol 15(12):968–973PubMed
28.
29.
30.
Bruix J, Sherman M, Llovet JM, et al. (2001) EASL panel of experts on HCC, clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefPubMed
31.
Pahwa ABK, Beckett K, Channual S, et al. (2014) Efficacy of the American association for the study of liver disease and barcelona criteria for the diagnosis of hepatocellular carcinoma. Abdom Imaging 39(4):753–760CrossRefPubMed
32.
Ebara M, Ohto M, Watanabe Y, et al. (1986) Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 159(2):371–377CrossRefPubMed
33.
Nishie A, Asayama A, Ishigami K, et al. (2014) Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma. J Gastroenterol Hepatol 29(3):561–567CrossRefPubMed
34.
Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMed
35.
Darnell A, Forner A, Rimola J, Reig M, et al. (2015) Liver imaging reporting and data system with mr imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275(3):698–707CrossRefPubMed
36.
Saito K, Moriyasu F, Sugimoto K, et al. (2011) Diagnostic efficacy of gadoxetic acid-enhanced MRI for hepatocellular carcinoma and dysplastic nodule. World J Gastroenterol 17(30):3503–3509CrossRefPubMedPubMedCentral
37.
Haimerl M, Wächtler M, Platzek I, et al. (2013) Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions. BMC Med Imaging 13:41CrossRefPubMedPubMedCentral
38.
van den Bos IC, Hussain SM, Terkivatan T, Zondervan PE, de Man RA (2006) Stepwise carcinogenesis of hepatocellular carcinoma in the cirrhotic liver: demonstration on serial MR imaging. J Magn Reson Imaging 24:1071–1080CrossRefPubMed
39.
International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef
40.
Channual S, Tan N, Siripongsakun S, et al. (2015) Gadoxetate disodium-enhanced MRI to differentiate dysplastic nodules and grade of hepatocellular carcinoma: correlation with histopathology. AJR Am J Roentgenol 205(3):546–553CrossRefPubMed
41.
Asayama Y, Tajima T, Nishie A, et al. (2011) Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 80:e243–e248CrossRefPubMed
42.
Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–798CrossRefPubMed
43.
Shanbhogue AK, Prasad S, Takahashi N, Vikram R, Sahani DV (2011) Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 258(3):673–693CrossRefPubMed
44.
Chung YE, Kim M, Park YN, et al. (2009) Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29(3):683–700CrossRefPubMed
45.
Han JK, Choi BI, Kim TK, et al. (1997) Hilar cholangiocarcinoma: thin-section spiral CT findings with cholangiographic correlation. Radiographics 17(6):1475–1485CrossRefPubMed
46.
Soyer P, Bluemke DA, Reichle R, et al. (1995) Imaging of intrahepatic cholangiocarcinoma: 2. Hilar cholangiocarcinoma. AJR Am J Roentgenol 165(6):1433–1436CrossRefPubMed
47.
Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24(2):189–199CrossRefPubMed
48.
Seidensticker R, Seidensticker M, Doegen K, et al (2016) Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract;8732521.
49.
Maithel SK, Gamblin TC, Kamel I, et al. (2013) Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 119(22):3929–3942CrossRefPubMed
50.
Jeong HT, Kim M, Chung YE, et al. (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201(4):W603–W611CrossRefPubMed
51.
Piscaglia FI, Iavarone M, Galassi M, et al. (2015) Cholangiocarcinoma in cirrhosis: value of hepatocyte specific magnetic resonance imaging. Dig Dis 33(6):735–744CrossRefPubMed
52.
Lodge JP (2000) Modern surgery for liver metastases. Cancer Imaging 11(1):77–85CrossRef
53.
54.
Schneider G, Maas R, Schultze Kool L, et al. (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Investig Radiol 38(2):85–94CrossRef
55.
Sahani DV, Kalva S, Fischman AJ, et al. (2005) Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 185(1):239–246CrossRefPubMed
56.
del Frate C, Bazzocchi M, Mortele KJ, et al. (2002) Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 225(3):766–772CrossRefPubMed
57.
Papanikolaou N, Prassopoulos P, Eracleous E, et al. (2001) Contrast-enhanced magnetic resonance cholangiography versus heavily T2-weighted magnetic resonance cholangiography. Investig Radiol 36(11):682–686CrossRef
58.
Lee VS, Krinsky G, Nazzaro CA, et al. (2004) Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography. Radiology 233(3):659–666CrossRefPubMed
59.
Fayad LM, Kamel I, Mitchell DG, Bluemke DA (2005) Functional MR cholangiography: diagnosis of functional abnormalities of the gallbladder and biliary tree. AJR Am J Roentgenol 184(5):1563–1571CrossRefPubMed
60.
Sheppard DA, Allan L, Martin P, et al. (2004) Contrast-enhanced magnetic resonance cholangiography using mangafodipir compared with standard T2 W MRC sequences: a pictorial essay. J Magn Reson Imaging 20(2):256–263CrossRefPubMed
61.
Park MS, Kim K, Yu JS, et al. (2004) Early biliary complications of laparoscopic cholecystectomy: evaluation on T2-weighted MR cholangiography in conjunction with mangafodipir trisodium-enhanced 3D T1-weighted MR cholangiography. AJR Am J Roentgenol 183(6):1559–1566CrossRefPubMed
62.
Ke Z, Hao X, Ning W, Mao-Heng Z, Yu-Fei F (2015) Fibrinolysis status in the Budd-Chiari syndrome in China. Blood Coagul Fibrinolysis 26(7):721–726PubMed
63.
Abraham SC, Kamath P, Eghtesad B, Demetris AJ, Krasinskas AM (2006) Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 30(11):1454–1461CrossRefPubMed
64.
Krishnan P, Fiel M, Rosenkrantz AB, et al. (2012) Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol 198(2):370–376CrossRefPubMed
65.
Cruite I, Schroeder M, Merkle EM, Sirlin CB (2010) Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 195(1):29–41CrossRefPubMed
66.
Goodwin MD, Dobson J, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31(6):1547–1568CrossRefPubMed
67.
Davenport MS, Viglianti V, Al-Hawary MM, et al. (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266(2):452–461CrossRefPubMed
68.
Kim SY, Park S, Wu EH, et al. (2015) Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses. AJR Am J Roentgenol 204(6):1220–1227CrossRefPubMed
69.
Motosugi U, Ichikawa T, Sou H, et al. (2009) Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 30(4):849–854CrossRefPubMed
70.
Tanimoto A, Higuchi N, Ueno A (2012) Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 11(2):91–97CrossRefPubMed
71.
Bollow M, Taupitz M, Hamm B, et al. (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7(1):126–132CrossRefPubMed
72.
Péporté AR, Sommer W, Nikolaou K, Reiser MF, Zech CJ (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82(3):e101–e106CrossRefPubMed
Metadata
Title
Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging
Authors
Stephanie Channual
Anokh Pahwa
David S. Lu
Steven S. Raman
Publication date
01-09-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 9/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0767-y

Other articles of this Issue 9/2016

Abdominal Radiology 9/2016 Go to the issue

OriginalPaper

Natural history of liver imaging reporting and data system category 4 nodules in MRI

Pictorial Essay

Clinical implications for imaging of vascular invasion in hepatocellular carcinoma

Classics in Abdominal Imaging

The dog ear sign

OriginalPaper

Superselective transcatheter arterial embolization in patients with acute peripancreatic bleeding complications: review of 44 cases

Commentary

Should Caroli’s disease be in the Todani classification?

JSAR

Massive splenic infarction and splenic venous thrombosis observed in a patient with acute splenic syndrome of sickle cell traits on contrast-enhanced thin-slice computed tomography
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits